Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact

Videos

Home / Videos

About Us

SIWA’s 318H monoclonal antibody targets a biomarker on cancer cells, senescent cells, and microbially-infected cells. Our initial focus is on life-threatening cancers and related diseases with an unmet medical need (i.e., eligible for FDA Fast-tracking). We expect to file our first IND in late 2022.

Recent News

SIWA Therapeutics, Inc. Presents New Data at the November 2022 American Association for Cancer Research Aging and Cancer Conference
SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study
SIWA Therapeutics, Inc. Appoints Deborah Wince-Smith to Board of Directors

JOIN OUR MAILING LIST

Navigation

Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact